Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific)

2026-05-21 — Genmab A/S (Nasdaq: GMAB) announced it will present/publish 23 abstracts across ASCO 2026 (Chicago, May 29–June 2) and EHA 2026 (Stockholm, June 11–14), including 20 abstracts on epcoritamab, a subcutaneous CD3xCD20 T‑cell–engaging bispecific antibody. Genmab highlighted four oral presentations and said the data will span epcoritamab monotherapy, combination regimens, fixed-duration use, outpatient administration, and earlier lines of therapy. Key oral sessions include the first full Phase 3 EPCORE DLBCL‑1 results comparing epcoritamab monotherapy vs investigator’s choice chemotherapy in relapsed/refractory large B‑cell lymphoma, and additional Phase 3 EPCORE FL‑1 data evaluating epcoritamab + rituximab/lenalidomide (R²) vs R² in relapsed/refractory follicular lymphoma. Three additional abstracts cover trials-in-progress for late-stage investigational candidates rinatabart sesutecan (Rina‑S; FRα ADC) and petosemtamab (EGFRxLGR5 bispecific). The announcement underscores Genmab’s pipeline progress and potential expansion of epcoritamab use; investigational uses’ safety/efficacy are not established.